Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Pomy Shrestha"'
1
Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC
Autor: Pasi A. Janne, Joseph Mostillo, Pomy Shrestha, Ruoyang Zhang, Pang-Dian Fan, Frédérique Cantero
Publikováno v: Journal of Clinical Oncology. 40:TPS3161-TPS3161
TPS3161 Background: Although first-line treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib improved survival in patients (pts) with advanced/metastatic EGFR-mutated ( EGFRm) non-small cell lung cancer (NS
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3381d981392221942819d48619dd9eb5
https://doi.org/10.1200/jco.2022.40.16_suppl.tps3161
Zobrazit plný text záznamu
3
Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD
Autor: Xiao Wu, Pomy Shrestha, James F. Donohue, Alejhandra Lei, Weily Soong
Publikováno v: Respiratory Medicine. 116:41-48
This was a one-year, Phase III randomized, double-blind, parallel-group, active-control study investigating the long-term safety and tolerability of twice-daily aclidinium 400 μg/formoterol 12 μg versus formoterol 12 μg.Eligible patients were male
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b291565250cabd9adfbda99b6aa8d8e1
https://doi.org/10.1016/j.rmed.2016.05.007
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje